跳至主要内容
临床试验/NCT00714857
NCT00714857已完成2 期

Population Pharmacokinetics of Dexmedetomidine in ICU Patients

University of Turku1 个研究点 分布在 1 个国家目标入组 21 人开始时间: 2007年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
21
试验地点
1
主要终点
Pharmacokinetic parameters

研究概览

简要总结

Dexmedetomidine is a new, highly selective and potent alpha2-adrenoreceptor agonist registered for sedation of patients in intensive care units. Although the pharmacokinetics of dexmedetomidine have been studied previously also in an ICU setting, there is no information on the pharmacokinetics of long-lasting (>48 hours) dexmedetomidine infusions in humans.

The aim of this study is to study the pharmacokinetics of long-lasting dexmedetomidine infusions in ICU patients using the population pharmacokinetics approach.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years.
  • Need for dexmedetomidine sedation (determined by the responsible physician).
  • Predicted length of dexmedetomidine sedation ≥ 48 hours.
  • Written informed consent from the patient or the relatives of the participating patient.

排除标准

  • A previous history of intolerance to the study drug or related compounds and additives.
  • Existing significant haematological, endocrine, metabolic or gastrointestinal disease

研究组 & 干预措施

1

Experimental

Patients receiving dexmedetomidine sedation

干预措施: Dexmedetomidine (Drug)

结局指标

主要结局

Pharmacokinetic parameters

时间窗: Blood samples are taken three times daily for characterizing the pharmacokinetic parameters

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Timo Iirola

MD

University of Turku

研究点 (1)

Loading locations...

相似试验